Zoetis Inc. $ZTS Shares Sold by Pictet Asset Management Holding SA

Key Points

• Pictet Asset Management trimmed its Zoetis stake by 10.3% in Q4, selling 276,479 shares and leaving it with 2,405,623 shares (about 0.55% of the company) valued at roughly $302.7 million.
• Zoetis beat quarterly expectations, reporting $1.48 EPS (vs. $1.40 est.) and $2.39 billion in revenue (vs. $2.36 billion est.), and set FY 2026 guidance of 7.00–7.10 EPS (analysts forecast ~7.02 EPS).
• The company announced a quarterly dividend of $0.53 ($2.12 annual, ~1.8% yield; ex-dividend Apr 20, payable June 2), while analyst coverage remains mixed with an average rating of Hold and an average price target of $152.25.

Pictet Asset Management Holding SA lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 10.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,405,623 shares of the company's stock after selling 276,479 shares during the period. Pictet Asset Management Holding SA owned 0.55% of Zoetis worth $302,683,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC boosted its stake in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new position in Zoetis during the fourth quarter valued at about $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the third quarter worth about $31,000. Finally, Holos Integrated Wealth LLC acquired a new stake in Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is currently owned by institutional investors.

Get Zoetis SMS alerts:

Sign Up

Zoetis Price Performance

ZTS opened at $116.92 on Monday. The stock has a market cap of $49.18 billion, a price-to-earnings ratio of 19.42, a PEG ratio of 1.78 and a beta of 0.98. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a fifty day moving average price of $120.83 and a 200 day moving average price of $125.28.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm's revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts forecast that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is 35.22%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ZTS shares. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. BTIG Research restated a "buy" rating and issued a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Piper Sandler reaffirmed a "neutral" rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $152.25.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.